SHARE
COPY LINK

HEALTH

Why has Zurich’s coronavirus vaccination plan been delayed?

Switzerland’s most populous canton is lagging behind the majority of the country when it comes to vaccinations.

Why has Zurich's coronavirus vaccination plan been delayed?
Photo: Arne Dedert / POOL / AFP

With a population of 1.5 million people, almost one in five people who live in Switzerland live in the canton of Zurich. 

But despite a relatively centralised population and some of the best access to resources in one of the world’s wealthiest countries, Zurich is lagging behind when it comes to vaccinating its population. 

What is the situation in Zurich? 

As at February 2nd, 2021, Zurich is vaccinating slower than 21 of Switzerland’s 26 cantons on a per capita basis. 

Zurich has vaccinated just 2.99 percent of its residents, which is slower than the Swiss average of 3.64. 

Only Bern, Neuchâtel, Aargau and Fribourg are vaccinating slower. 

UPDATED: Which Swiss cantons are vaccinating fastest against coronavirus? 

Is this a flaw of Zurich’s vaccine rollout – and how will things run in the future? 

What is Zurich’s vaccination strategy?

Cantonal authorities told Watson that the vaccination planning is a “logistical challenge with many unknown variables”. 

Zurich started vaccinations on January 4th – more than a week after the first vaccinations started on December 23rd 

Zurich started vaccinations at the Institute for Travel Medicine on Hirschengraben, which can carry out 600 vaccinations per day. 

According to the canton’s vaccination strategy, which was released in December, after risk groups are prioritised, health workers will get the jab in February. 

READ MORE: How can I get vaccinated for Covid-19 in Switzerland? 

Members of the general public were to be vaccinated from March at large vaccination centres across the canton, however the NZZ reported in January that this is now likely to start in April. 

When these centres hit full stride, an estimated 5,000 to 8,000 people will be vaccinated across the cantons. 

Why has the vaccine rollout been delayed? 

According to the NZZ, Zurich’s vaccination plan may have been too ambitious. 

Zurich wanted to set up six large vaccination centres, however cantonal authorities are still on the lookout for operators. 

Medical entities in Zurich have been reluctant to participate, citing low remuneration and a lack of staff. 

“We will not apply to operate a vaccination centre,” said Urs Müller, the CEO of Bülach Hospital. 

The centres require approximately 100 people daily, which Müller said the hospital does not have. 

“If we had so many staff available in the hospital that we could simply assign for other tasks, then we would not run our business very efficiently.”

Operators are paid CHF50 per vaccination, which Müller says is too low for operators to recoup their costs. 

“We already have enough to struggle with the financial damage caused by the pandemic,” Müller said. 

‘Accelerated with more vaccine’

Cantonal authorities have blamed hold ups in vaccine procurement for the delays rather than organisational hurdles, saying “timetable in the canton of Zurich could only be accelerated with more vaccine.”

By the second last week of January, approximately 24,989 vaccinations were carried out in Zurich. 

Delays in delivery however will continue to be felt into February, with 90,000 instead of the promised 113,000 Biontech/Pfizer doses delivered before the end of February

People can register to be vaccinated in Zurich at the following link

 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.
For members

HEALTH

Which medications in Switzerland are set to become more expensive?

The cost of medications in Switzerland is already quite a bit higher than elsewhere in Europe. And now certain drugs will become even pricier.

Which medications in Switzerland are set to become more expensive?

Swiss consumers pay significantly more for their medicines than those in neighbouring European countries. 

This is what emerges from various data published over the years.

“In Switzerland, we pay far too much for medicines compared to abroad,” Matthias Müller, a spokesperson for SantéSuisse, an umbrella group for Swiss health insurance providers, told Swiss media in 2023. 

Even the price of many generic medicines is twice as high in Switzerland as in nine EU countries.

For instance, generics are on average 48 percent cheaper in Belgium, Denmark, Germany, Finland, France, Great Britain, the Netherlands, Austria and Sweden than in Switzerland, according to a price comparison.

And prices for a number of commonly-used drugs will rise even further in the near future.

Why is that?

The Federal Office of Public Health (FOPH) is adapting a new model for calculating the distribution margin. 

A distribution margin is the difference between the distributor’s cost of acquiring goods and the price at which those goods are sold.

From July 1st, 2024, inexpensive medicines whose factory price is less than, or equal to, 15 francs will become more expensive.

This change will affect more than half of medications currently being sold in Switzerland.

As a result of this move, “additional costs of several hundred million will be passed on to patients,” according to Intergenrika, which represents generic drug manufacturers in Switzerland. 

In a nutshell, consumers will pay slightly lower prices for medicines that were previously more expensive, but will also end up paying more  for those that are currently cheaper – like generics.

Which meds will become more expensive?

Pain medications are among those set to become pricier.

One of them is ibuprofen, a popular anti-inflammatory.

While a box of 20 400-mg tablets today costs 5.92 francs, its price will practically double to 11 francs from July 1st.

Though its manufacturing cost will remain the same as today – 1.58 francs – the distribution margin will increase from 4.19 to 9.09 francs.

The same goes for another often-used pain medication, Ponstan.

Ten 500-mg tablets will cost 11.21 francs instead of 6.19 currently.

The manufacturer will continue to charge 1.82 francs for the drug, but the distribution margin will increase from 4.22 to 9.11 francs.

And even generic drugs, which are cheaper – and often by much – will get pricier, at consumers’ expense.

Will some drugs be cheaper?

Yes, some will become slightly less expensive.

One example is the anticoagulant Rivaroxaban whose price will drop from 281 to 267 francs.

READ ALSO: Why you will pay more for certain drugs in Switzerland 2024?

SHOW COMMENTS